Outlook Therapeutics, Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 30 Sep 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 26 Jun 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 18 Feb 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Quarterly report filed late (NT 10-Q)
The company filed Form NT 10-Q with the SEC on 17 Aug 2026, notifying investors that its quarterly report would be late. Late filings can point to accounting or business problems, though the reason is sometimes routine.
More details →Outlook Therapeutics, Inc. — Overview & Financial Snapshot
Outlook Therapeutics, Inc. (NasdaqCM: OTLK) is a Healthcare company, ranked #6,574 of 6,774 companies globally and #3,818 of 4,000 in United States on PositoAI, with a Positivity Score of -26,143. Its market capitalisation is ₹1,294.88 Cr ($137.18M), P/E ratio is -0.8 and P/B ratio is -13.20. It currently has 3 active red flags (PosiRed) and 1 yellow flag (PosiYellow, 2/10 points) on record.
For financial statements, ratio trends and score history, Go Deep →